HC Wainwright Has Pessimistic Opinion of AXSM Q3 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – HC Wainwright cut their Q3 2027 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $1.84 for the quarter, down from their prior estimate of $1.92. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2027 earnings at $2.52 EPS and FY2027 earnings at $4.80 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.38. The company had revenue of $259.69 million during the quarter, compared to analysts’ expectations of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The firm’s quarterly revenue was up 51.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.94) EPS.

A number of other equities research analysts have also issued reports on AXSM. BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price objective for the company. Zacks Research upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. Mizuho reduced their target price on shares of Axsome Therapeutics from $284.00 to $272.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 4th. UBS Group decreased their target price on shares of Axsome Therapeutics from $256.00 to $239.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. Finally, Needham & Company LLC increased their price target on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and an average target price of $267.58.

Axsome Therapeutics Stock Up 1.2%

Shares of AXSM opened at $133.96 on Tuesday. Axsome Therapeutics has a 52-week low of $123.00 and a 52-week high of $260.19. The company has a quick ratio of 1.34, a current ratio of 1.42 and a debt-to-equity ratio of 1.21. The stock has a fifty day simple moving average of $176.31 and a two-hundred day simple moving average of $197.60. The company has a market capitalization of $7.05 billion, a PE ratio of -43.78 and a beta of 0.86.

Insider Buying and Selling

In other news, COO Mark Jacobson sold 10,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares of the company’s stock, valued at $2,086,500. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Hollencrest Capital Management lifted its holdings in shares of Axsome Therapeutics by 400.0% in the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after acquiring an additional 160 shares during the last quarter. ABS Investment Management LLC purchased a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $171,339,000. ABS Direct Equity Fund LLC purchased a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $60,000. Jacobi Capital Management LLC purchased a new position in shares of Axsome Therapeutics during the 3rd quarter worth approximately $47,000. Finally, Silvant Capital Management LLC acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at approximately $66,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau.

Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.